News
Academy
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in Medicine
Conference CoverageConference Listing
Pharmaceutical Executive
Partner Perspectives
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers
Subscribe
Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
Spotlight -
  • Latest Executive Roundtables
  • Asembia 2025
  • Sales Effectiveness
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Academy
    • Partner Perspectives
    • Subscribe
Advertisement

Article

February 10, 2010

Study Links Paxil to Breast Cancer Patient Deaths

The popular antidepressant is associated with up to 91 percent increase in risk of death in patients undergoing tamoxifen treatment for breast cancer.

Bad news for GSK and generics manufacturers of Paxil came this week in the form of a new study published in BMJ (the British Medical Journal) linking antidepressant paroxetine (marketed by GSK as Paxil) with increased mortality rates in breast cancer patients over the age of 66.

The observational study, conducted by a team at the Sunnybrook Health Sciences Centre in Toronto, looked at data on 2,430 patients treated with tamoxifen for breast cancer along with a single SSRI (selective serotonin reuptake inhibitor) for depression. The women were all 66 or older, and all were from the province of Ontario. Those taking paroxetine for 25 percent of the duration of their tamoxifen treatment had a 24 percent increase in risk of death from breast cancer. Patients taking paroxetine for 75 percent of the duration saw their risk jump to 91 percent.

The researchers report that these percentages were confined to paroxetine; other SSRIs, like fluoxetine (Prozac) and sertraline (Zoloft) had no effect on mortality rate.

David Juurlink, a member of the research team, explained that the discrepancy comes from paroxetine’s method of reuptake inhibition. While the other SSRIs settle for temporarily inhibiting a particular enzyme (CYP2D6), paroxetine’s effect is not reversible. Unfortunately, CYP2D6 is essential for metabolizing tamoxifen, so with paroxetine permanently inactivating this enzyme, the cancer-fighting drug is essentially neutralized.

“There’s been a suspicion for years about possible negative effects of paroxetine on drugs like these,” Juurlink said. “This is the first study to actually quantify it.”

The data excluded women younger than 66 for the simple reason that data sets are much less complete—or nonexistent—for those populations in Canada. However, Juurlink believes physicians will (and should) discontinue using paroxetine for all patients being treated with tamoxifen, and is confident that further studies on younger populations will yield similar results.

“You’ll soon see warnings from the FDA and Health Canada, which have already been sniffing around this for a while,” he predicted.

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Related Videos
Related Content
Advertisement
Credit: Tada Images | stock.adobe.com, The FDA has authorized the use of updated COVID-19 vaccines for the upcoming fall season, with eligibility limited to adults aged 65 years and older as well as individuals who have at least one underlying medical condition that places them with a high risk for severe COVID-19
August 28th 2025

FDA Authorizes New COVID Vaccines with Restrictions on Eligibility

Davy James
Peter Ax, UpScriptHealth
August 28th 2025

Tariffs and Drug Prices: Understanding the Impact on Pharmaceuticals

Miranda Schmalfuhs
FDA Approves Ionis Pharmaceuticals’ Dawnzera for Hereditary Angioedema
August 28th 2025

FDA Approves Ionis Pharmaceuticals’ Dawnzera for Hereditary Angioedema

Don Tracy, Associate Editor
Navigating Distrust: Pharma in the Age of Social Media
August 28th 2025

Navigating Distrust: Pharma in the Age of Social Media

Miranda Schmalfuhs
Alan Crowther
August 28th 2025

What the Most Favored Nation Executive Order Means to Pharma Brands and Future Implications

Mike Hollan
Lawsuits Likely as Federal Authorities Roll Back Longstanding Vaccine Guidelines
August 28th 2025

Lawsuits Likely as Federal Authorities Roll Back Longstanding Vaccine Guidelines

Don Tracy, Associate Editor
Related Content
Advertisement
Credit: Tada Images | stock.adobe.com, The FDA has authorized the use of updated COVID-19 vaccines for the upcoming fall season, with eligibility limited to adults aged 65 years and older as well as individuals who have at least one underlying medical condition that places them with a high risk for severe COVID-19
August 28th 2025

FDA Authorizes New COVID Vaccines with Restrictions on Eligibility

Davy James
Peter Ax, UpScriptHealth
August 28th 2025

Tariffs and Drug Prices: Understanding the Impact on Pharmaceuticals

Miranda Schmalfuhs
FDA Approves Ionis Pharmaceuticals’ Dawnzera for Hereditary Angioedema
August 28th 2025

FDA Approves Ionis Pharmaceuticals’ Dawnzera for Hereditary Angioedema

Don Tracy, Associate Editor
Navigating Distrust: Pharma in the Age of Social Media
August 28th 2025

Navigating Distrust: Pharma in the Age of Social Media

Miranda Schmalfuhs
Alan Crowther
August 28th 2025

What the Most Favored Nation Executive Order Means to Pharma Brands and Future Implications

Mike Hollan
Lawsuits Likely as Federal Authorities Roll Back Longstanding Vaccine Guidelines
August 28th 2025

Lawsuits Likely as Federal Authorities Roll Back Longstanding Vaccine Guidelines

Don Tracy, Associate Editor
About
Advertise
Contact Us
Editorial Board
Editorial Submission Guidelines
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.